噻托溴铵联合沙美特罗替卡松粉吸入治疗慢性阻塞性肺疾病稳定期的疗效

目的：研究噻托溴铵联合沙美特罗替卡松粉吸入治疗慢性阻塞性肺疾病稳定期的疗效。方法：选择从2012年9月至2014年9月在我院接受治疗的 COPD 稳定期患者116例实施研究。根据随机数字法随机将116例患者划分为观察组以及对照组各58例，对照组患者予以沙美特罗替卡松粉治疗，观察组患者在此基础上另予以噻托溴铵治疗，对比两组患者的疗效，两组治疗前后的 FEV1及 FVC水平，以及两组治疗后的药物不良反应。结果：观察组的显效率为72．41％，总有效率为98．28％，高于对照组的50．00％，84．48％，差异有统计学意义（P＜0．05）。两组治疗前的 FEV1及 FVC 水平相比，差异无统计学意义（P＞0．05）。观察组治疗后的 FEV1及 FVC 水平高于对照组，差异有统计学意义（P＜0．05）。观察组的总并发症发生率是25．86％（15／58），与对照组的12．07％（7／58）相比，差异无统计学意义（P ＞0．05）。结论：联用噻托溴铵与沙美特罗替卡松粉对 COPD 患者进行治疗，疗效较好，且安全性亦较高，值得在临床治疗过程中推广。

Tiotropium Combined with Salmeterol and Fluticasone Propionate Powder Inhalation in Treating Patients with COPD in Stable Stage

Objective: To study the effect of tiotropium combined with salmeterol and fluticasone propi -onate powder inhalation in the treatment of patients with chronic obstructive pulmonary disease (COPD) in stable stage.Methods: 116 cases of patients with stable COPD treated in our hospital from September 2012 to September 2014 were selected as objects.According to the digital method, 116 patients were randomly divided into observation group and control group , with 58 cases in each group, the control group was given with salme -terol and fluticasone propionate powder , patients in the observation group on the basis of it another given tiotropium for treatment, compared the efficacy of the two groups, FEV1 and FVC levels in the two groups be-fore and after treatment, and two groups after the treatment of drug adverse reactions .Results:The total effec-tive rate of observation group was 98.28% (57/58), which was significantly higher than the control group of 84.48% (49/58), the difference was statistically significant (P <0.05).Compared with the FEV1 and FVC levels in the two groups before treatment, there was no statistically significant difference (P >0.05).Observa-tion group of FEV1 and FVC levels after treatment were significantly higher than the control group , the differ-ence was statistically significant (P <0.05).The total incidence of complications of the observation group was 25.86% (15/58), and 12.07% (7/58) in the control group, there was no statistically significant difference (P >0.05).Conclusion: Combined with tiotropium bromide and salmeterol and fluticasone propionate in the treatment of COPD patients, curative effect is better, and the safety is high, is worth popularizing in the clini-cal course of treatment.